{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:40Z","timestamp":1760186560771,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.hoc.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,11,29]],"date-time":"2015-11-29T14:31:13Z","timestamp":1448807473000},"page":"63-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors"],"prefix":"10.1016","volume":"30","author":[{"given":"Claire K.","family":"Mulvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily K.","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2015.09.002_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.hoc.2015.09.002_bib3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hoc.2015.09.002_bib4","first-page":"5969","article-title":"Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas","volume":"50","author":"Reubi","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2015.09.002_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.09.002_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hoc.2015.09.002_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","article-title":"Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period","volume":"40","author":"Anthony","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.hoc.2015.09.002_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/02841869109092409","article-title":"Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group","volume":"77","author":"di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.hoc.2015.09.002_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hoc.2015.09.002_bib14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/bja\/aen237","article-title":"Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist","volume":"101","author":"Castillo","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.hoc.2015.09.002_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004311-199703540-00009","article-title":"Anesthesia for patients with carcinoid syndrome","volume":"35","author":"Vaughan","year":"1997","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.hoc.2015.09.002_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CRD.0b013e31824c866e","article-title":"Carcinoid heart disease","volume":"20","author":"Palaniswamy","year":"2012","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.hoc.2015.09.002_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2015.09.002_bib18","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"3","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.hoc.2015.09.002_bib19","doi-asserted-by":"crossref","unstructured":"Kulke MH, H\u00f6rsch D, Caplin M, et\u00a0al. Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). Presented at: 2015 European Cancer Congress; September 25\u201329; Vienna, Austria. Abstract 37LBA.","DOI":"10.1016\/S0959-8049(16)31951-7"},{"key":"10.1016\/j.hoc.2015.09.002_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.09.002_bib21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(86)91435-2","article-title":"Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon","volume":"2","author":"Eriksson","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2015.09.002_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.hoc.2015.09.002_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107327481101800207","article-title":"A\u00a0review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract","volume":"18","author":"Strosberg","year":"2011","journal-title":"Cancer Control"},{"key":"10.1016\/j.hoc.2015.09.002_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.hoc.2015.09.002_bib25","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.09.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib28","article-title":"A\u00a0randomized open-label phase II study of everolimus alone or in combination with pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial","author":"Kulke","year":"2015","journal-title":"Eur Neuroendocrine Tumor Soc"},{"key":"10.1016\/j.hoc.2015.09.002_bib29","first-page":"35","article-title":"The action of interferon alpha on human carcinoid tumours","volume":"3","author":"Oberg","year":"1992","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.hoc.2015.09.002_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0016-5085(00)70143-0","article-title":"Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells","volume":"118","author":"Detjen","year":"2000","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2015.09.002_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000080748","article-title":"Interferon-alpha: regulatory effects on cell cycle and angiogenesis","volume":"80","author":"Rosewicz","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.hoc.2015.09.002_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2015.09.002_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000201404","article-title":"Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours","volume":"57","author":"Faiss","year":"1996","journal-title":"Digestion"},{"key":"10.1016\/j.hoc.2015.09.002_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hoc.2015.09.002_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hoc.2015.09.002_bib37","first-page":"4573","article-title":"Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells","volume":"60","author":"von Wichert","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2015.09.002_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1677\/ERC-10-0157","article-title":"Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung","volume":"17","author":"Righi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1677\/ERC-07-0202","article-title":"Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors","volume":"15","author":"Moreno","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.09.002_bib42","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2015.09.002_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.4_suppl.157","article-title":"Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)","volume":"30","author":"Yao","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib44","doi-asserted-by":"crossref","unstructured":"Yao J, Fazio, N, Singh, S, et\u00a0al. Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. European Cancer Congress 2015. Abstr 5LBA.","DOI":"10.1016\/S0959-8049(16)31928-1"},{"key":"10.1016\/j.hoc.2015.09.002_bib45","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.22554","article-title":"Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors","volume":"109","author":"Zhang","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1535-6108(02)00031-4","article-title":"VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis","volume":"1","author":"Inoue","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2015.09.002_bib47","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4004","article-title":"SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon 2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)","volume":"33","author":"Yao","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.4104","article-title":"A\u00a0phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors","volume":"28","author":"Kunz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1016\/j.hoc.2015.09.002_bib50","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1200\/jco.2008.26.15_suppl.15545","article-title":"Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors","volume":"26","author":"Venook","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2407-14-184","article-title":"Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study","volume":"14","author":"Berruti","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.09.002_bib53","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib54","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","article-title":"Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours","volume":"109","author":"Ahn","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2015.09.002_bib55","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4100","article-title":"A\u00a0phase II study of axitinib in advanced carcinoid tumors: preliminary analysis","volume":"33","author":"Cives","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib57","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.2011.76","article-title":"Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours","volume":"104","author":"Medley","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib58","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","article-title":"A\u00a0Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors","volume":"91","author":"Ansell","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.COC.0000054535.19808.F4","article-title":"Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity","volume":"27","author":"Ansell","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.20466","article-title":"A\u00a0Phase II trial of gemcitabine for metastatic neuroendocrine tumors","volume":"101","author":"Kulke","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib61","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib62","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib63","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/j.hoc.2015.09.002_bib64","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V","article-title":"Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study","volume":"73","author":"Bukowski","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2015.09.002_bib65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2015.09.002_bib66","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 3; abstr 179","key":"10.1016\/j.hoc.2015.09.002_bib68","article-title":"Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. Gastrointestinal Cancer Symposium","volume":"32","author":"Fine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib69","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib70","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib71","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib72","doi-asserted-by":"crossref","first-page":"760","DOI":"10.6004\/jnccn.2009.0052","article-title":"Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules","volume":"7","author":"Bushnell","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.hoc.2015.09.002_bib73","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/COC.0b013e3182005768","article-title":"Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver","volume":"35","author":"Kennedy","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib74","unstructured":"Ruszniewski P, et\u00a0al. 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. European Cancer Congress 2015. Abstr 6LBA."},{"key":"10.1016\/j.hoc.2015.09.002_bib75","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP-NETs update: biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.hoc.2015.09.002_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11523-009-0128-7","article-title":"Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Capdevila","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.hoc.2015.09.002_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e15004","article-title":"Phase I expansion trial of an oral TORC1\/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET)","volume":"31","author":"Mita","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:02:41Z","timestamp":1760184161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858815001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889858815001379"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2015.09.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}